BioSpace News Archive

Deals

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 7, 2024

UroGen Pharma Ltd. today announced the grants of inducement restricted stock units (“RSUs”) and an option (“Option”) to 15 new employees in connection with their employment with UroGen.

June 7, 2024
·
2 min read
Pharm Country

Innovation in Pharmacogenomic Testing for Over a Decade

Principle Diagnostics Laboratory, a leader in Pharmacogenomic testing, proudly celebrates a decade of pioneering advancements in personalized medicine.

June 7, 2024
·
3 min read
Pharm Country

STRATA Skin Sciences’ TheraClear®X Acne Therapy System Found to be Safe and Effective for Acne Lesions Across All Fitzpatrick Skin Types with Favorable Tolerability and Patient Satisfaction as Published in Peer Reviewed Journal

STRATA Skin Sciences, Inc. announces the publication of a clinical study titled, " A 7-Week Open-Label Trial Evaluating the Safety and Efficacy of TheraClear®X for Mitigating Mild-to-Moderate Acne in Healthy Adolescents and Young Adults,” in the June 2024 issue of the Journal of Clinical and Aesthetic Dermatology.

June 7, 2024
·
5 min read
Deals

IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global MarketTrading to commence effective on the market open June 14, 2024

IRADIMED CORPORATION announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.”

June 7, 2024
·
5 min read
BioMidwest

Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation

SeaStar Medical Holding Corporation announces the publication of a peer-reviewed article in NatureScientific Reports that describes the mechanism of action of the Company’s Selective Cytopheretic Device in the immunomodulation of excessive inflammation.

June 7, 2024
·
6 min read
FDA

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

ChromaDex Corp. today announced that the U.S. Food & Drug Administration (FDA) granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for NRC, the company’s product candidate for the treatment of Ataxia Telangiectasia (AT).

June 7, 2024
·
8 min read
Biotech Bay

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

Vistagen today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update.

June 7, 2024
·
2 min read
Deals

Asensus Surgical Announces Signing of Definitive Merger Agreement with KARL STORZ

Asensus Surgical, Inc. today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with KARL STORZ Endoscopy-America, Inc.

June 7, 2024
·
7 min read
Genetown

Combined General Meeting of June 24, 2024

Biophytis SA will hold its Combined General Meeting on June 24, 2024 at 2pm at Sorbonne Université - Amphi Herpin - 4 Place Jussieu, 75005 Paris.

June 7, 2024
·
3 min read
Business

David F. Melbourne Jr. Promoted to Chief Executive Officer of AquaBounty; Sylvia Wulf to Continue as Non-Executive Board Chair

The Board of Directors of AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability

June 7, 2024
·
8 min read